Current hair regeneration methods show promise but face challenges in maintaining cell effectiveness and creating the right environment for hair growth.
A permanent hair loss solution could involve reprogramming hairfollicles to resist DHT using mRNA and siRNA. However, high costs, safety concerns, and the pharmaceutical industry's preference for ongoing treatments over one-time cures are major obstacles, with finasteride and minoxidil remaining standard treatments.
RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hairfollicle growth and restore hair pigment without the negative side effects of immunosuppressants.
Hair loss treatments like minoxidil, finasteride, and dutasteride, with mixed results and suggestions for combining treatments or considering hair transplants. Some users experience no improvement or side effects.
Oleic acid, microneedling, and emu oil are discussed as potential hair growth treatments, with some users expressing skepticism about their effectiveness. Minoxidil and finasteride are recommended as current reliable treatments until more proven solutions are available.
Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.